Core Viewpoint - A class action has been filed against Concorde International Group, Ltd. for allegedly being involved in a fraudulent "pump-and-dump" scheme that misled investors during the class period from April 21, 2025, to July 14, 2025 [1][2]. Allegations - The complaint alleges that Concorde failed to disclose critical information regarding a fraudulent stock promotion scheme that involved misinformation on social media and impersonation of financial professionals [2]. - Insiders and affiliates reportedly used offshore accounts to facilitate the dumping of shares during a price inflation campaign, misleading investors about the company's true financial health [2]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price, leading to materially misleading representations about its business prospects [2]. Stock Price Movement - Concorde's share price rose dramatically from an initial public offering price of $4.00 to a peak of $31.06, despite a lack of fundamental news justifying such an increase [3]. - On July 10, 2025, the stock price plummeted approximately 80% to $5.66, and it has since continued to decline to around $2.00 [3]. Shareholder Actions - Shareholders may participate in the class action and those wishing to serve as lead plaintiffs must submit their papers by May 18, 2026 [4]. - Shareholders can choose to remain absent class members and still be eligible for recovery without participating in the case [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Concorde International Group, Ltd. (CIGL) securities during a specified period, alleging that the company was involved in a fraudulent stock promotion scheme [1][2]. Allegations - The lawsuit claims that during the class period, Concorde failed to disclose critical information, including its involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2] - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign, misleading investors about the company's true financial health [2] - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price, rendering their positive statements materially misleading [2] Stock Price Movement - Prior to July 10, 2025, Concorde's share price increased dramatically from an initial public offering price of $4.00 to a peak of $31.06, despite a lack of fundamental news justifying such a rise [3] - Following the peak, the share price plummeted approximately 80% to $5.66 on July 10, 2025, and has since continued to decline to around $2.00 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by May 18, 2026, although participation is not required to be eligible for recovery [4] - The class action is structured on a contingency fee basis, meaning shareholders will incur no fees or expenses [5]

Core Viewpoint - A class action lawsuit has been filed against POMDoctor Ltd. for allegedly engaging in a pump-and-dump scheme that defrauded investors, leading to significant losses following an initial public offering [1]. Allegations - The lawsuit claims that POMDoctor's share price increased from the IPO price of $4.00 to a peak of $6.09 without any fundamental news justifying the rise [1]. - Investigations revealed that POMDoctor used social media to promote its stock through impersonators posing as legitimate financial advisors, creating a buying frenzy among retail investors [1]. - On December 10, 2025, the share price plummeted approximately 91% to $0.50, and it has since further declined to around $0.40 [1]. Disclosure Failures - The defendants allegedly failed to disclose that POMDoctor was involved in a stock promotion scheme that relied on misinformation and impersonation [1]. - It is claimed that insiders or affiliates used offshore accounts to facilitate the coordinated selling of shares during the price inflation campaign [1]. - POMDoctor's public statements and risk disclosures reportedly omitted any mention of the false rumors and artificial trading activity affecting the stock price [1]. Shareholder Actions - Shareholders may be eligible to participate in the class action and must submit their papers to the court by April 7, 2026, if they wish to serve as lead plaintiffs [1]. - Shareholders can choose to remain absent class members without participating in the case and still be eligible for recovery [1].

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) for allegedly engaging in a pump-and-dump scheme that defrauded investors, resulting in significant financial losses [1][2]. Allegations - The lawsuit alleges that OST's co-CEO Lai Kui Sen and financial advisor Yan Zhao, along with at least fifteen co-conspirators, orchestrated a scheme that generated over $110 million in illicit proceeds through securities fraud and wire fraud [2][3]. - The fraudulent activities began in April 2025, involving a series of manipulated securities offerings that allowed co-conspirators to acquire OST shares at extremely low prices, often for no consideration [3][4]. Market Impact - During the class period, OST's market capitalization inflated from approximately $22 million (stock price of $0.78 on April 14, 2025) to over $1 billion (peak stock price of $9.40 on June 26, 2025) due to the fraudulent promotional campaign [4]. - On June 26, 2025, a selloff led to a catastrophic loss of over $950 million, representing more than 94% of OST's market capitalization, with the stock price plummeting from an intraday high of $9.40 to a closing price of $0.55 [5]. Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by April 17, 2026, to serve as lead plaintiff, representing other class members in the litigation [6]. - The law firm Robbins LLP, known for its focus on shareholder rights litigation, is handling the case on a contingency fee basis, meaning shareholders incur no fees or expenses [7].

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. (NASDAQ: OST) for allegedly engaging in a pump-and-dump scheme that defrauded investors, resulting in significant financial losses [1]. Allegations - The lawsuit alleges that from April 2025, OST's co-CEO Lai Kui Sen and co-conspirators orchestrated a fraudulent sequence of securities offerings, placing the majority of OST shares in the hands of at least fifteen co-conspirators for minimal or no cost [1]. - The U.S. Department of Justice unsealed a criminal indictment on September 12, 2025, charging Lai Kui Sen and financial advisor Yan Zhao with conspiracy to commit securities fraud and wire fraud, with the scheme netting over $110 million in illicit proceeds [1]. - The fraudulent promotional campaign inflated OST's market capitalization from approximately $22 million (stock price of $0.78 on April 14, 2025) to over $1 billion (peak stock price of $9.40 on June 26, 2025) [1]. Financial Impact - On June 26, 2025, OST investors faced devastating losses, with over $950 million (more than 94%) of OST's market capitalization wiped out in a single day as the stock price plummeted from an intraday high of $9.40 to a closing price of $0.55 [1].

Core Viewpoint - A class action has been filed against China Liberal Education Holdings Ltd. for allegedly participating in a fraudulent pump-and-dump scheme that harmed investors by over $300 million [1][3]. Allegations - China Liberal Education Holdings Ltd. is accused of coordinating with scammers to manipulate the company's stock price through illegal means, including advertisements on social media platforms like Facebook and Instagram [2]. - Victims were recruited into WhatsApp groups where scammers posed as financial advisors, encouraging them to buy manipulated securities, allowing co-conspirators to sell at inflated prices [2]. Market Impact - The fraud was revealed on January 30, 2025, leading to an immediate collapse in the stock price, resulting in significant financial losses for investors [3]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action have until March 31, 2026, to file their papers with the court [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Company Background - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants, alleging violations of the Securities Exchange Act due to misleading statements and a fraudulent stock promotion scheme that led to significant losses for investors [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., with a lead plaintiff deadline set for April 3, 2026 [1][5]. - The class action targets individuals and entities that purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025, who suffered damages as a result [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [3]. - It is claimed that the defendants orchestrated a "pump-and-dump" scheme, where the stock price was artificially inflated through a social media promotion involving impersonators posing as legitimate financial advisors [2][3]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, and sale of medical devices, with its flagship product being the artificial heart "SynCardia TAH" [2]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [2].

Core Viewpoint - A class action lawsuit has been filed against China Liberal Education Holdings, Ltd. for alleged securities fraud involving a "pump-and-dump" scheme that resulted in estimated losses exceeding $300 million [2][3]. Group 1: Lawsuit Details - The lawsuit, titled Atul Shah, et al. v. China Liberal Education Holdings Ltd., et al., was filed in the Southern District of New York and involves claims against the company's officers, directors, and associated service providers [1]. - The class period for the lawsuit is defined as January 22, 2025, to January 30, 2025, during which investors can seek appointment as lead plaintiff [1][3]. - The allegations include violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Group 2: Investor Participation - Investors who purchased or acquired common stock of CLEU during the class period are eligible to seek lead plaintiff status but are not required to do so to participate in any future recovery [3]. - The plaintiffs intend to apply for lead plaintiff status and seek the appointment of Morris Kandinov LLP as lead counsel [3]. Group 3: Financial Implications - The alleged "pump-and-dump" scheme is said to have caused losses estimated to exceed $300 million, indicating significant financial implications for investors involved [2].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Fly-E Group, Inc. following a damaging report that led to a significant decline in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Fly-E Group, Inc. and is looking into whether the company and its officers or directors have engaged in securities fraud [1]. - The investigation was prompted by a report from The Bear Cave, which accused Fly-E of stock manipulation and being involved in a pump-and-dump scheme [3]. Group 2: Stock Performance - Following the publication of The Bear Cave report, Fly-E's stock price experienced a sharp decline over several consecutive trading sessions [3]. Group 3: Company Background - Fly-E Group, Inc. is under scrutiny for producing products that The Bear Cave claims endanger public safety in New York [3]. - Pomerantz LLP has a long history in corporate and securities class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].